Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin (SURPASS-3)
Molcula e investigacin Qu es Tirzepatida (LY3298176) y cmo acta sobre GIP y GLP-1 Tirzepatida (LY3298176) es un agonista dual de los receptores GIP y GLP-1 estudiado dentro de la investigacin incretnica moderna
A 2025 radiographic study found an average 7% reduction in midfacial volume for every 10 kilograms of total weight lost, with most of the change occurring in superficial facial fat pads
Recently, the GIP/GLP-1R co-agonist tirzepatide has gone through several randomized controlled trials and was approved by the FDA for T2DM and obesity in 2022 and 2023, respectively
This article does not constitute medical advice
Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
US$ 22.59
US$ 25.50
:format(webp))
US$ 20.04
US$ 28.60
